预约演示
更新于：2025-05-24
Drospirenone
屈螺酮
更新于：2025-05-24
概要
基本信息
药物类型 小分子化药 |
别名 1,2-Dihydrospirorenone、6β,7β;15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone、Dehydrospirorenone + [13] |
作用方式 拮抗剂、激动剂、抑制剂 |
作用机制 AR拮抗剂(雄激素受体拮抗剂)、MR拮抗剂(盐皮质激素受体拮抗剂)、PR激动剂(孕激素受体激动剂) |
治疗领域 |
在研适应症 |
非在研适应症 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2019-05-23), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H30O3 |
InChIKeyMETQSPRSQINEEU-HXCATZOESA-N |
CAS号67392-87-4 |
关联
44
项与 屈螺酮 相关的临床试验NCT06608186
Can Drospirenone be Used to Prevent LH Surge in Controlled Ovarian Stimulation in PCOS Cases
NCT06345560
Pharmacokinetics of Drospirenone Only Pills in Obese Thai Women: A Pre- and Post-Bariatric Surgery Study
NCT06345586
Drospirenone Only Pills and Cervical Mucus Changes in Obese Thai Women: A Pre- and Post-Bariatric Surgery Study
100 项与 屈螺酮 相关的临床结果
登录后查看更多信息
100 项与 屈螺酮 相关的转化医学
登录后查看更多信息
100 项与 屈螺酮 相关的专利（医药）
登录后查看更多信息
1,439
项与 屈螺酮 相关的文献（医药）2025-12-31GYNECOLOGICAL ENDOCRINOLOGY
Effect over coagulation and fibrinolysis parameters of a prolonged release 24 + 4 daily use regime contraceptive formulation containing 2 mg dienogest/0.02 mg ethinylestradiol
Article
作者: Regidor, Pedro-Antonio ; Angulo, Alicyoy ; Colli, Enrico
BACKGROUND:
A prolonged release combined oral contraceptive (COC) pill, containing 2 mg dienogest (DNG)/0.02 mg ethinylestradiol (EE) in a 24 + 4 daily dosing regimen has recently been approved in Europe.
OBJECTIVE:
To determine if this COC impacts coagulation and fibrinolytic factors in comparison to an immediate release COC containing 3 mg drospirenone (DRSP)/0.02 mg EE.
METHOD:
Forty-four patients received the novel product, and forty-seven the comparator (immediate release formulation) during nine complete cycles. Coagulation and fibrinolytic parameters were evaluated: activated protein C resistance ratio, Antithrombin III (AT III), C-reactive protein, Factor VII, Factor VIII, and D-Dimer.
RESULTS:
Compared to baseline, at the end of the study both groups displayed significantly higher mean values for AT III: 1.06 mg/mL (standard deviation [SD], 95% CI, 0.98-1.15) for the DNG/EE formulation and 1.04 mg/mL (SD 95% CI, 0.96-1.12) for the comparator (p = 0.0006 and p = 0.0009, respectively). D-dimer showed a non-significant slight reduction in the DNG/EE group, from 276.62 ng/mL (SD, 95% CI, 228.92-334.26) before treatment to 243.98 ng/mL (SD, 95% CI, 192.45-309.31) ng/mL after treatment. Contrarily, the comparator displayed a non-significant rise in D-dimer values from 246.46 ng/mL (SD, 95% CI, 205.44-295.66) ng/mL to 275.30 ng/mL (SD, 95% CI 219.21-345.75; p = 0.4520). All other parameters showed no significant differences before and after the treatment for both groups.
CONCLUSION:
The COC 2 mg DNG/0.02 mg EE was not associated with any meaningful changes in the analyzed coagulation and fibrinolytic parameters indicating that a prolonged release formulation does not impact on these factors.
CLINICAL TRIAL REGISTRY:
EudraCT: 2019-0018-77-97.
2025-07-01JOURNAL OF HAZARDOUS MATERIALS
Screening and risk assessment of priority organic micropollutants for control in reclaimed water in China
Article
作者: Wang, Zijian ; Sun, Kaicheng ; Wen, Zhao ; Meng, Qingling ; Xue, Honghai
Organic micropollutants (OMPs) in reclaimed water have been frequently detected over the past decades, posing significant risks to ecosystems and human health. Given the complexity of these pollutants and the differences in their risk and toxicity, current assessments remain incomplete. This study conducted a large-scale investigation of OMPs in reclaimed water across China and developed a comprehensive multi-criteria integrated scoring method based on OMP toxicity and exposure potential. This method aims to protect aquatic organisms and human health by screening and prioritizing OMPs in reclaimed water, classifying their priority levels, and creating a prioritized control list. The study quantified OMP exposure potential, environmental persistence, bioaccumulation, and impacts on ecology and human health. The survey detected 369 OMPs from 11 chemical classes, with 325 compounds passing pre-selection. According to the prioritization scheme, 29 OMPs were identified as high priority, 171 as medium priority, and 125 as low priority. The BPs and Other Industrial Chemicals categories had the highest average maximum concentrations, followed by HPCCs and PAEs. High-priority pollutants were dominated by PAHs and PCBs, each comprising 31.03 %. Medium- and low-priority groups were mainly composed of Pesticides. PAHs and PCBs showed higher risk quotients, indicating significant ecological risks, while PCB 126, BaP, and PFOA exhibited high toxicity and potential health risks. This study provides valuable information for controlling priority pollutants in Chinese reclaimed water and establishes a foundation for OMP risk management. Future research should intensify monitoring to ensure the safe and sustainable use of water resources.
2025-06-01European Journal of Obstetrics & Gynecology and Reproductive Biology
Reply to ‘Critical appraisal of “Comparison of combined oral contraceptives and dienogest for endometriosis-associated pain”’
Letter
作者: Cianci, Stefano ; Palumbo, Marco ; Caruso, Salvatore ; Caruso, Giuseppe ; Gulino, Ferdinando Antonio ; Sareri, Marco Iraci
A polemic in response to Zahid N et al; Eur J Obstet Gynecol Reprod Biol 2025;307:267.In the article, it was not possible to perform either a randomized study or a blinded study because the groups of women were enrolled at different times between Oct. 2018 to March 2023.This was due to the study of specific regimens and formulations of the combined oral contraceptives (COCs), approved over time, used to modulate/treat the symptoms of endometriosis; the most recently enrolled women used COCs containing oestetrol combined with drospirenone.However, the VAS was used from the beginning of enrolment, and we continued to create the database using the same tools.Contrary to the criticism by Zahid et al., Bonferroni′s test was adopted for multiple comparisons.Although we noted that oestradiol- and oestetrol-containing COCs are more effective than ethinylestradiol COCs, and comparable to dienogest in reducing pain symptoms, we emphasized that there is a need to increase the number of investigations using COCs containing natural and native estrogens rather than ethinylestradiol in order to understand which is more effective.While medications may be necessary for extended periods, it is crucial to ensure that each woman receives the safest hormone treat ment, administered through the most appropriate route.Considering the significant number of individuals affected by endometriosis, it is essential to adopt a more balanced approach that places equal emphasis on both safety and efficacy.
100 项与 屈螺酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 避孕 | 美国 | 2019-05-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 子宫内膜异位症 | 临床3期 | 斯洛伐克 | - | 2021-07-24 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 30 | 願願鏇齋醖鹹製鹹鹹夢 = 齋鑰廠網製糧選艱艱鏇 鹹願遞選鹽遞糧襯糧廠 (淵醖壓齋夢獵糧壓壓艱, 構願願範夢獵簾廠餘糧 ~ 襯顧繭積膚獵鏇餘簾衊) 更多 | - | 2024-04-19 | |||
願願鏇齋醖鹹製鹹鹹夢 = 築糧遞膚觸齋觸選網衊 鹹願遞選鹽遞糧襯糧廠 (淵醖壓齋夢獵糧壓壓艱, 鏇艱遞觸鹽繭壓膚壓膚 ~ 餘醖憲夢餘簾選壓鏇顧) 更多 | |||||||
N/A | - | (Nonobese participants) | 繭淵餘衊壓淵願網鏇顧(壓觸鹹淵窪繭網憲憲廠) = 夢膚鹹遞糧築衊淵遞艱 觸衊壓夢獵構遞鹹鹹鹽 (構築鬱觸餘糧艱鹽壓齋, 1.3 ~ 5.8) | 积极 | 2023-12-01 | ||
(Obese participants) | 繭淵餘衊壓淵願網鏇顧(壓觸鹹淵窪繭網憲憲廠) = 簾選窪鹽衊糧願淵遞壓 觸衊壓夢獵構遞鹹鹹鹽 (構築鬱觸餘糧艱鹽壓齋, 0.8 ~ 7.3) | ||||||
N/A | 32 | (Drospirenone and Ethinyl Estradiol) | 簾襯願淵簾繭觸鏇憲壓(蓋觸襯窪壓夢顧積鹹遞) = 觸餘鹽選鹹繭憲觸蓋膚 齋繭膚鹹夢網選醖醖獵 (憲膚憲壓艱艱鏇簾範簾, 築觸製網選艱鹽鹽窪糧 ~ 艱製糧遞鬱窪獵繭繭築) 更多 | - | 2017-03-20 | ||
Placebo (Placebo) | 簾襯願淵簾繭觸鏇憲壓(蓋觸襯窪壓夢顧積鹹遞) = 選襯鹽築網簾構艱製淵 齋繭膚鹹夢網選醖醖獵 (憲膚憲壓艱艱鏇簾範簾, 蓋鏇夢鹽糧壓淵醖製積 ~ 遞衊壓鏇範夢鹹製醖願) 更多 | ||||||
N/A | - | - | Drospirenone-only pill | 壓糧鬱願艱範衊遞醖築(鹽築範網築遞糧壓築範) = 蓋顧蓋襯蓋廠鏇蓋窪鬱 鹹鏇顧糧遞顧廠獵構醖 (獵艱製範顧餘選襯艱壓 ) 更多 | 积极 | 2015-11-02 | |
Desogestrel-only pill | 壓糧鬱願艱範衊遞醖築(鹽築範網築遞糧壓築範) = 範網製鬱糧網淵願構觸 鹹鏇顧糧遞顧廠獵構醖 (獵艱製範顧餘選襯艱壓 ) 更多 | ||||||
N/A | 97 | (Oral Contraceptive - 1) | 齋鏇鏇遞鏇膚壓衊鹽獵(膚糧憲醖膚構襯願鏇膚) = 鹹願窪鬱製顧選窪築範 糧遞壓夢範艱艱窪糧製 (鑰遞願願鏇鏇顧衊鹽鬱, 17) 更多 | - | 2014-06-06 | ||
Flutamide - 2 (Flutamide - 2) | 齋鏇鏇遞鏇膚壓衊鹽獵(膚糧憲醖膚構襯願鏇膚) = 網獵網簾壓鹽衊築選衊 糧遞壓夢範艱艱窪糧製 (鑰遞願願鏇鏇顧衊鹽鬱, 14) 更多 | ||||||
临床2期 | 4 | Ethinyl Estradiol (YAZ)+Drospirenone (Drospirenone and Ethinyl Estradiol (YAZ)) | 構淵壓鬱醖鬱範憲艱鬱(願鹽築積齋觸繭夢網構) = 選艱顧簾製繭積鏇積網 積構積觸夢範顧鬱齋醖 (選鬱鏇膚艱糧糧繭願觸, 2.1213) 更多 | - | 2014-01-16 | ||
Placebo (Placebo Tablets) | 構淵壓鬱醖鬱範憲艱鬱(願鹽築積齋觸繭夢網構) = 齋積餘憲願簾獵淵膚壓 積構積觸夢範顧鬱齋醖 (選鬱鏇膚艱糧糧繭願觸, 33.9411) 更多 | ||||||
N/A | 腹部肥胖 sex steroids | aldosteronism | 63 | 壓齋範淵遞繭鬱鹽鏇淵(繭憲構構壓鹹蓋顧積積) = 積蓋繭觸鏇醖襯獵糧鑰 製簾鹽願鬱獵廠窪鏇衊 (遞鹹願鬱築鑰廠製膚鹽 ) 更多 | 积极 | 2012-09-01 | ||
Hormone Replacement Therapy (estradiol hemihydrate 1 mg, drospirenone 2 mg daily) | 壓齋範淵遞繭鬱鹽鏇淵(繭憲構構壓鹹蓋顧積積) = 蓋鏇顧鬱鹽壓鏇網窪選 製簾鹽願鬱獵廠窪鏇衊 (遞鹹願鬱築鑰廠製膚鹽 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用